NewAmsterdam Pharma (NAMS) EPS (Weighted Average and Diluted) (2023 - 2025)
Historic EPS (Weighted Average and Diluted) for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to -$0.61.
- NewAmsterdam Pharma's EPS (Weighted Average and Diluted) fell 23888.89% to -$0.61 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.05, marking a year-over-year increase of 888.89%. This contributed to the annual value of -$2.56 for FY2024, which is 1906.98% down from last year.
- According to the latest figures from Q3 2025, NewAmsterdam Pharma's EPS (Weighted Average and Diluted) is -$0.61, which was down 23888.89% from -$0.15 recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma's EPS (Weighted Average and Diluted) ranged from a high of -$0.15 in Q2 2025 and a low of -$1.06 during Q1 2024
- Over the past 3 years, NewAmsterdam Pharma's median EPS (Weighted Average and Diluted) value was -$0.51 (recorded in 2023), while the average stood at -$0.53.
- As far as peak fluctuations go, NewAmsterdam Pharma's EPS (Weighted Average and Diluted) skyrocketed by 6842.11% in 2024, and later plummeted by 23888.89% in 2025.
- Quarter analysis of 3 years shows NewAmsterdam Pharma's EPS (Weighted Average and Diluted) stood at -$0.6 in 2023, then plummeted by 58.33% to -$0.95 in 2024, then surged by 35.79% to -$0.61 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.61 in Q3 2025, compared to -$0.15 in Q2 2025 and -$0.34 in Q1 2025.